A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.

@article{Sternberg2013ARD,
  title={A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update.},
  author={Cora N Sternberg and Robert Edward Hawkins and John Wagstaff and Pamela Salman and Jozef Mardiak and Carlos Henrique Barrios and Juan Jos{\'e} Zarb{\'a} and Oleg A. Gladkov and Eunsik Lee and Cezary A. Szczylik and Lauren McCann and Stephen D. Rubin and Mei Chen and Ian D Davis},
  journal={European journal of cancer},
  year={2013},
  volume={49 6},
  pages={1287-96}
}
BACKGROUND In this randomised phase III study (VEG105192; NCT00334282), pazopanib previously demonstrated statistically and clinically meaningful improvement of progression-free survival versus placebo in patients with advanced/metastatic renal cell carcinoma (mRCC). Final overall survival (OS) and updated safety results are now reported. METHODS Treatment-naive or cytokine-pretreated mRCC patients (n=435) stratified and randomised (2:1) to pazopanib 800 mg daily or placebo, were treated… CONTINUE READING